Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: Clin Cancer Res. 2013 May 20;19(14):3844–3855. doi: 10.1158/1078-0432.CCR-13-0505

Fig 5. CD16x33 BiKE triggers NK cell degranulation and cytokine production against relapse/refractory CD33+ AML targets.

Fig 5

(A) CD33 surface expression measured by flow cytometry analysis of bone marrow samples from 10 patients with relapse/refractory AML. Percent expression and median fluorescence intensity (MFI) are shown for each sample. (B and C) Purified NK cells isolated from two healthy donors were cultured with each refractory AML sample (E:T ratio of 2:1) (n=20 separate assays). Cells were treated with or without 5 ug/mL of CD16x33 BiKE. After 4 hours in culture, intracellular CD107a degranulation, TNF-α, and IFN-γ were determined by flow cytometry for (B) CD33+ AML targets (n=16 from 8 CD33+ AML targets derived from 2 donors each) and (C) CD33− AML targets (n=4 from 2 CD33− AML targets derived from 2 donors each). (*P<0.05; **P<0.01, ***P<0.001).